Suppr超能文献

根据 DIN EN ISO 15197 评估 27 个血糖监测系统的系统准确性。

System accuracy evaluation of 27 blood glucose monitoring systems according to DIN EN ISO 15197.

机构信息

Institute for Diabetes-Technology at the University of Ulm, Germany.

出版信息

Diabetes Technol Ther. 2010 Mar;12(3):221-31. doi: 10.1089/dia.2009.0128.

Abstract

BACKGROUND

Blood glucose (BG) monitoring systems enable diabetes patients to effectively control and adjust their therapy. BG monitoring systems with a Conformité Européenne (CE) label should meet the standard DIN EN ISO 15197:2003: > or =95% of the BG results shall fall within +/-15 mg/dL of the reference method at BG concentrations <75 mg/dL and within +/-20% at BG concentrations > or =75 mg/dL. We intended to verify if BG monitoring systems with a CE label fulfill these minimum accuracy requirements.

METHODS

We evaluated 27 BG monitoring systems from 18 manufacturers for system accuracy according to DIN EN ISO 15197:2003. Twenty-four systems were compared with the glucose oxidase reaction (YSI 2300 glucose analyzer [YSI Life Sciences, Yellow Springs, OH]) and three systems with the hexokinase reaction (Hitachi 917 [Roche Diagnostics GmbH, Mannheim, Germany]). Duplicate measurements of 100 blood samples with a defined distribution of BG concentrations from 20 mg/dL to 600 mg/dL from > or =100 subjects were included in the evaluation.

RESULTS

Sixteen of the 27 BG monitoring systems fulfilled the minimum accuracy requirements of the standard, i.e., > or =95% of their results showed the minimum acceptable accuracy. Overall, the mean percentage of results showing the minimum acceptable accuracy was 95.2 +/- 5.2%, ranging from 80.0% to 100.0%.

CONCLUSIONS

More than 40% of the evaluated BG monitoring systems did not fulfill the minimum accuracy requirements of DIN EN ISO 15197:2003. As inaccurate BG monitoring systems bear the risk of false treatment decisions by the diabetes patient and subsequent possible severe health injury, manufacturers should regularly and effectively check the quality of BG meters and BG test strips.

摘要

背景

血糖(BG)监测系统使糖尿病患者能够有效控制和调整治疗方案。具有欧洲符合性(CE)标签的 BG 监测系统应符合 DIN EN ISO 15197:2003 标准:在 BG 浓度<75mg/dL 时,<95%的 BG 结果应在参考方法的 +/-15mg/dL 内,在 BG 浓度>=75mg/dL 时,应在 +/-20%内。我们旨在验证具有 CE 标签的 BG 监测系统是否满足这些最低精度要求。

方法

我们根据 DIN EN ISO 15197:2003 评估了来自 18 家制造商的 27 种 BG 监测系统的系统精度。24 种系统与葡萄糖氧化酶反应(YSI 2300 葡萄糖分析仪[YSI Life Sciences,Yellow Springs,OH])进行了比较,3 种系统与己糖激酶反应(罗氏诊断公司的 Hitachi 917[Roche Diagnostics GmbH,曼海姆,德国])进行了比较。评估中包括了来自>=100 名受试者的 100 份血液样本的 100 次重复测量,这些样本的 BG 浓度分布从 20mg/dL 到 600mg/dL。

结果

27 种 BG 监测系统中有 16 种满足标准的最低精度要求,即>=95%的结果显示出最低可接受的精度。总体而言,显示最低可接受精度的结果的平均百分比为 95.2+/-5.2%,范围为 80.0%至 100.0%。

结论

评估的 BG 监测系统中超过 40%未满足 DIN EN ISO 15197:2003 的最低精度要求。由于不准确的 BG 监测系统存在糖尿病患者做出错误治疗决策并随后可能导致严重健康伤害的风险,制造商应定期有效地检查 BG 计和 BG 测试条的质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验